Title : Development and in-vitro evaluation of K-carrageenan bead for sustained delivery of Repaglinide
Controlled drug delivery systems release drugs at a pre-set pace in order to maintain a constant drug concentration over a set period of time while minimising side effects. Repaglinide is a low-dose drug that is administered immediately before a meal to lower blood glucose levels by releasing insulin from pancreas, which acts on the cells. Since repaglinide is totally passed by bile, it is a healthy substitute for diabetic patients along impaired kidney function. To retain therapeutic concentrations of repaglinide in blood plasma and reduce side effects such like hypoglycaemia, kappa (κ)- carrageenan beads were used to establish a regulated and long-lasting drug delivery system. Drugs and enzymes, trapped using κ-carrageenan like a trapping medium. The Inotropic gelatin method is used to make micro beads. Optimized drug release formulation in vitro was tested in hydrochloric acid (0.1N) and phosphate buffer pH 7.4 using dissolution test apparatus. To learn drug release rate and process, in vitro data was fitted to zero and first order, Korsmeyer-Peppas and Higuchi models. Repaglinide adopted a method for controlling the release of microbead release control system, according to the Korsmeyer-Peppas model. This method eliminates the possibility of an alkaline microenvironment, which was previously created by using gastro-retentive drug delivery systems.